Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 878-881

  Contino Pépin, Christiane ^a   Parat, Audrey ^a   Périno, Sandrine ^a   Lenoir, Christine ^b,c   Vidal, Michel ^b,c   Galons, Hervé ^b,c   Karlik, Stephen ^d   Pucci, Bernard ^a  

^a UNIVERSITY OF AVIGNON   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Angiogenesis inhibitors; EAE; Multiple sclerosis; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIAL CELLS; HUMANS; MODELS, CHEMICAL; MULTIPLE SCLEROSIS; NEOVASCULARIZATION, PATHOLOGIC; THALIDOMIDE;

ANIMALIA;

EID: 58549098710     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.118     Document Type: Article

References (28)

1. Folkman J. N. Eng. J. Med. 285 (1971) 1182
2. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Nat. Rev. Drug Discov. 3 (2004) 391
3. Trachsel E., and Neri D. Adv. Drug Deliv. Rev. 58 (2006) 735
4. Rybak J.N., Trachsel E., Scheuermann J., and Neri D. ChemMedChem 2 (2007) 22
5. Jasseron S., Contino-Pépin C., Maurizis J.C., Ollier M., and Pucci B. Eur. J. Med. Chem. 38 (2003) 825
6. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4082
7. Périno S., Contino-Pépin C., Satchi-Fainaro R., Butterfield C., and Pucci B. Bioorg. Med. Chem. Lett. 14 (2004) 421
8. Kourlas H., and Abrams P. Clin. Ther. 29 (2007) 1850
9. Pandya N.M., Dhalla N.S., and Santani D.D. Vasc. Pharmacol. 44 (2006) 265
10. Kirk S.L., and Karlik S.J. J. Autoimmun. 21 (2003) 353
11. Minagar A., Jy W., Jimenez J.J., and Alexander J.S. Neurol. Res. 28 (2006) 230
12. Sleijfer S., Kruit W.H.J., and Stoter G. Eur. J. Cancer 40 (2004) 2377
13. Sharief M.K., and Thompson E.J. J. Neuroimmunol. 38 (1992) 27
14. Melchert M., and List A. Int. J. Biochem. Cell Biol. 39 (2007) 1489
15. Noguchi T., Fujimoto H., Sano H., Miyajima A., Miyachi H., and Hashimoto Y. Bioorg. Med. Chem. Lett. 15 (2005) 5509
16. Périno S., Contino-Pépin C., Jasseron S., Rapp M., Maurizis J.C., and Pucci B. Bioorg. Med. Chem. Lett. 16 (2006) 1111
17. Steinman L., and Zamvil S.S. Ann. Neurol. 60 (2006) 12
18. 3OD, δ): δ = 174.0; 173.3; 170.4; 168.4; 167.9; 154.6; 134.6; 124.8; 116.9; 115.4; 105.5; 104.4; 81.9; 75.8; 73.4; 72.6; 71.7; 71.4; 71.1; 69.0; 62.4; 61.3; 49.0; 40.0; 36.3; 30.8; 28.96; 28.2; 22.4.
19. Muller G.W., Chen R., Huang S.Y., Corral L.G., Wong L.M., Patterson R.T., Chen Y., Kaplan G., and Stirling D.I. Bioorg. Med. Chem. Lett. 9 (1999) 1625
20. Bauer K.S., Dixon S.C., and Figg W.D. Biochem. Pharmacol. 55 (1998) 1827
21. Lepper E.R., Ng S.S.W., Gütschow M., Weiss M., Hauschildt S., Hecker T.K., Luzzio F.A., Eger K., and Figg W.D. J. Med. Chem. 47 (2004) 2219
22. Zhu X., Giordano T., Yu Q.S., Holloway H.W., Perry T.A., Lahiri D.K., Brossi A., and Greig N.H. J. Med. Chem. 46 (2003) 5222
23. Komorowski J., Jerczyńska H., Siejka A., Barańska P., Lawnicka H., Pawlowska Z., and Stepień H. Life Sci. 78 (2006) 2558
24. Edgell C.J., McDonald C.C., and Graham J.B. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 3734
25. Cell culture. EA.hy926 cells were serially cultured in DMEM (Invitrogen, Paisley, UK) containing 15% heat-inactivated FCS, 150 U/mL penicillin, 150 U/mL streptomycin, 2 mM l-glutamine, and 0.04% HAT (hypoxanthine, aminopterin, thymine) supplement (all from Invitrogen, Paisley, UK) and passaged weekly. For counting experiments, 30,000 cells were seeded on 6-well plates at J0 and were treated with products at the appropriate dose 12 h later. After 7 days of growing, cells were trypsinated and counted with a counter coulter. The NIH3T3 cells were serially cultured in DMEM containing 15% heat-inactivated FCS, 150 U/mL penicillin, 150 U/mL streptomycin, 2 mM l-glutamine and passaged weekly.
26. L'azou B., Fernandez P., Bareille R., Beneteau M., Bourget C., Cambar J., and Bordenave L. Cell Biol. Toxicol. 21 (2005) 127
27. Miyachi H., Azuma A., Ogasawara A., Uchimura E., Watanabe N., Kobayashi Y., Kato F., Kato M., and Hashimoto Y. J. Med. Chem. 40 (1997) 2858
28. Roscoe W.A., Kidder G.M., and Karlik S.J. Cell Commun. Adhes. 14 (2007) 57